Kalaris Therapeutics Inc

AlloVir is an American healthcare company and is one of the leading names around the globe in the development of Virus-Specific T-cell (VST) immunotherapies. Founded in 2013 and headquartered in Cambridge, Massachusetts, the firm is focussed on developing highly innovative, allogeneic, off-the-shelf VST therapy candidates which target twelve devastating viral infections with both treatment and prevention. The firm’s work is aimed at helping patients with T-cell deficiencies, many of whom currently have limited treatment options or no viable treatment at all. The company launched publicly in 2020 with an upsized IPO that raised $276.25m. Allovir is listed on the NASDAQ GS and trades its stock under the ticker ALVR. In November 2020 the ALVR share price was $34.55 and the company had a market cap of $2.13bn. The company’s platform is highly efficient, practising advanced VST profiling and antigen selection to induce the strongest T-cell immune responses. Their CytokinTM donor selection process ensures an efficient selection of carefully-screened donors. The firm maintains a pipeline of therapeutic candidates in pre-clinical and clinical trials targeting high-risk individuals, such as organ transplant patients and those suffering various chronic illnesses. Add ALVR stock to your eToro watchlist to get news and updates on this instrument.